When to start antiretroviral therapy in adults in low- and middle-income countries: Science and practice

Current Opinion in HIV and AIDS

Volumn 5, Issue 1, 2010, Pages 6-11

  Munderi, Paula ^a  

^a UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

Author keywords

Antiretroviral therapy; Low income and middle income countries; When to start treatment

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

BACTEREMIA; CD4 LYMPHOCYTE COUNT; CLINICAL PRACTICE; COMORBIDITY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; EARLY DIAGNOSIS; HEALTH CARE ACCESS; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION RISK; LOWEST INCOME GROUP; MEDICAL PRACTICE; MORBIDITY; MORTALITY; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEPSIS; SURVIVAL; TREATMENT INDICATION; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPING COUNTRIES; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMANS; POVERTY; PRACTICE GUIDELINES AS TOPIC; PROGRAM EVALUATION;

EID: 74349098557     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833384d3     Document Type: Review

References (45)

1. WHO/UNICEF/UNAIDS. Towards universal access: scaling up priority HIV/ AIDS interventions in the health sector. Progress report 2009.
2. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-510.
3. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource limited settings: towards universal access. Recommendations for a public health approach. 2006 revision.
4. Uganda Ministry of Health. National Antiretroviral Treatment Guidelines for Adults, Adolescents, and Children. 2nd ed. July 2008.
5. Vitoria M. Personal communication from unpublished survey of a review of National ART Guidelines from 26 LMIC. Geneva: WHO; August 2009.
6. Lowrance DH, Ndamage F, Kayirangwa E, et al. Adult clinical and immunologic outcomes of the National Antiretroviral Treatment Program in Rwanda during 2004-2005. J Acquir Immune Defic Syndr 2009; 52:49-55.
7. Chasombat S, McConnell MS, Siangphoe U, et al. National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr 2009; 50:506-512.
8. Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 2009; 151:241-251.
9. Micek MA, Gimbel-Sherr K, João Baptista A, et al. Loss to follow-up of adults in public HIV care systems in central Mozambique: identifying obstacles to treatment. J Acquir Immune Defic Syndr 2009; 52:397-405.
10. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www. aidsinfo.nih.gov.
11. Hammer S, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
12. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133-1144.
13. Sterne JA, May M, Costagliola D, et al., the When to Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
14. Kitahata MM, Gange SJ, Abraham GA, et al., for the NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
15. Lichtenstein K, Armon C, Buchacz K, et al. Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anaemia, or renal insufficiency. J Acquir Immune Defic Syndr 2008; 47:27-35.
16. Uy J, Armon C, Buchacz K, et al., the HOPS Investigators. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr 2009; 51:450-453.
17. Zolopa A, Andersen J, Komarow L, et al.; for the ACTG A5164 study team. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4:e5575. doi:10.1371/journal.pone. 0005575.
18. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
19. Lurie M, Williams B, Kumar P. The impact of antiretroviral therapy on the basic reproductive number, R0 [abstract MOPEB049]. 5th IAS Conference on HIV Pathogenesis; July 2009; Cape Town.
20. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
21. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897-1908.
22. Castelnuovo B, Manabe YC, Kiragga A, et al. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an Urban African cohort. Clin Infect Dis 2009; 49:965-972.
23. Tuboi SH, Schechter M, McGowan CC, et al. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr 2009; 51:615-623.
24. Brinkhof MWG, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 2009; 4:e5790
25. Yiannoutsos CT. Modelling AIDS survival after initiation of antiretroviral treatment by Weibull models with change points. J Int AIDS Soc 2009; 12:9.
26. Brinkhof MWG, Boulle A, Weigel R, et al. Mortality of HIV-infected patients starting antiretroviral therapy in Sub-Saharan Africa: comparison with HIVunrelated mortality. PLoS Med 2009; 6:e1000066.
27. Lewden C, Chêne G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72-77.
28. Nash D, Katyal M, Brinkhof MWG, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. For the ART-LINC Collaboration of IeDEAM. AIDS 2008; 22:2291-2302.
29. Ministry of Health STD/AIDS Control Programme, Uganda. Report of the provision of antiretroviral therapy in the public and private facilities in Uganda. September 2008.
30. Hladik W, Musinguzi J, Kirungi W, et al. The estimated burden of HIV/AIDS in Uganda, 2005-2010. AIDS 2008; 22:503-510.
31. Walensky RP, Wolf LL, Wood R, et al., for the CEPAC-International Investigators. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009; 151:157-166.
32. Elliot JH, Lynen L, Calmy A, et al. Rational use of antiretroviral therapy in lowincome and middle-income countries: optimizing regimen sequencing and switching. AIDS 2008; 22:1-15.
33. Bassett I, Regan S, Chetty S, et al. Who starts ART in Durban, South Africa?. . .Not everyone who should¡ [abstract WEAD102]. 5th IAS Conference on HIV Pathogenesis; July 2009; Cape Town.
34. Munderi P, Watera C, Nakiyingi J, et al. Survival and causes of death, 2 years after introduction of antiretroviral therapy in Africa: a historical cohort comparison in Entebbe, Uganda [abstract THLB0208]. Proceedings of the XVI International AIDS Conference; 13-18 August 2006; Toronto.
35. Rosen S, Mccoy A, Mazimba L, et al. Net cost of switching from stavudine to tenofovir in first line antiretroviral therapy in Zambia [abstract MOPED015]. 5th IAS Conference on HIV Pathogenesis; July 2009; Cape Town.
36. Kivela J,O'Brien D. Cost comparison of a strategy to minimize the toxicity of d4Tbased first-line antiretroviral regimens compared with the routine use of TDFbased first-line regimens in resource-limited settings [abstract MOPED017]. 5th IAS Conference on HIV Pathogenesis; July 2009; Cape Town.
37. Rosen S, Fox M. Quality versus quantity in antiretroviral treatment programs in resource-constrained countries: understanding the tradeoffs [abstract MOPED022]. IAS Conference on HIV Pathogenesis; July 2009; Cape Town.
38. Bendavid E, Bhattacharya J. The President's Emergency Plan for AIDS relief in Africa: an evaluation of outcomes. Ann Intern Med 2009; 150:10.
39. Nash D, Wu Y, Gandhi S, et al. Program-level determinants of low CD4 count ART initiation in cohorts of persons aged-6 years initiating ART in 8 sub-Saharan African countries [abstract WEAD103]. The International Center for AIDS Care and Treatment Programs (ICAP). 5th IAS Conference on HIV Pathogenesis; July 2009; Cape Town.
40. Hunt PW, Wools-Kaloustian K, Kimaiyo S, et al. Changing characteristics of HIV-infected patients initiating antiretroviral therapy in East Africa from 2003-2008 [abstract WEAD101]. 5th IAS Conference on HIV Pathogenesis; July 2009; Cape Town.
41. Le Paih M, McGuire M, Szumilin E, et al. Scale up impact on care access and early program attrition: seven years of providing ART in rural Malawi [abstract WEAD104]. 5th IAS Conference on HIV Pathogenesis; July 2009; Cape Town.
42. NIAID press release. Starting antiretroviral therapy earlier yields better clinical outcomes. Interim review leads to early end of clinical trial in Haiti. http:// www3.niaid.nih.gov/news/newsreleases/2009/CIPRA-HT-01.htm. [Accessed 17 September 2009].
43. ANRS 12336 TEMPRANO. Early antiretroviral treatment and/or early isoniazid prophylaxis against tuberculosis in HIV-infected adults. http://www.clinicaltrials. gov/ct2/show/NCT00495651. [Accessed 18 September 2009].
44. HIV Prevention Trials Network. Preventing sexual transmission of HIV with anti-HIV drugs. http://www.clinicaltrials.gov/ct2/show/NCT00074581. [Accessed 18 September 2009].
45. Kigozi IM, Loren MD, Martin JN, et al. Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. J Acquir Immune Defic Syndr 2009 [Epub ahead of print].